Translating MEG-based biomarkers to EEG-based outcome measures for Autism Spectrum Disorders
Translating MEG-based biomarkers to EEG-based outcome measures for Autism Spectrum Disorders
批准号:
9762202
负责人:
Tal Kenet
金额:
$21.06万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-08-13 至 2020-11-30
关键词:
AddressAftercareAgeAreaAuditoryBase of the BrainBiological MarkersBrainClinicClinicalClinical TrialsComplexComplex AnalysisCouplingDataData AnalysesData CollectionDevelopmentDiagnosisDouble-blind trialDrug TargetingElectroencephalographyEnsureEquipmentFutureGoalsHeterogeneityHumanIndividualInterventionIntervention TrialLocationMagnetoencephalographyMapsMeasuresMethodsNatureNoiseOutcomeOutcome MeasureParticipantPharmacologyPhasePlacebo EffectPopulationProcessPublic HealthPublishingRadialResearchRestRiskSensorySeveritiesSignal TransductionSiteSourceStandardizationSystemTactileTestingTranslatingTranslationsValidationWorkage groupautism spectrum disorderautistic childrenbasebehavior measurementdensitydesigndrug testinglaboratory equipmentneuromechanismneurophysiologynovelnovel strategiesportabilityresponsesensorsource localizationsuccesstheoriestherapy developmenttooltreatment trialuser-friendlyvibrotactile stimulation
中文摘要
摘要/总结
目前有一个明确的需要客观的大脑为基础的成果措施自闭症
谱系障碍(ASD)。结果测量是在临床或实验室检查之前使用的测量。
干预试验开始,以获得基线测量,然后在试验结束时重复,
以确定是否由于干预而发生了变化。目前,广大
ASD治疗试验中使用的大多数结果测量是基于行为测量,
通常是父母的,因此是主观的。即使在双盲试验中,
从安慰剂效应的措施污染的风险。因此,显然需要
实地的客观成果措施。其中一类潜在的结果指标是
基于大脑的由于最常见的临床实验室设备是简单的10-20 EEG系统,
ASD的理想的基于大脑的结果测量将使用这样的系统。但绝
大多数已知的ASD生物标志物,理论上具有结果测量潜力,
使用的设备过于复杂和昂贵,无法在临床上复制。
设置,并使用需要设置的范例,分析过于复杂的方法
在大量受试者中进行临床试验,受试者间变异性高。
在这里,我们提出了一个新的方法来解决这个问题。我们建议翻译三个
我们实验室或其他小组使用脑磁图确定的ASD生物标志物
(MEG)临床EEG。这项研究将集中在基于MEG的生物标志物上,这些生物标志物已经被认为是
与ASD诊断和严重程度相关,一个在听觉领域,一个在触觉领域,
域,和一个使用相对新颖的分析静息状态数据。临床翻译
EEG将明智地进行,通过结合MEG和EEG数据收集,然后
使用数据驱动的方法来验证结果。我们还将开发一个用户友好的工具箱
作为该过程的一部分,使数据分析标准化,使该过程易于移植,
在多个站点中保持一致。
最初的开发将使用10个典型的开发参与者进行,
10名ASD参与者,使用高密度同步EEG/MEG数据收集。结果将
然后使用每组15名新参与者进行验证,同时进行“临床EEG”(即,
最小的传感器位置)和高密度MEG数据收集。这个概念验证提案
将完全在现场进行,并将为未来跨多个地点的非现场研究奠定基础。
临床环境,理想情况下与正在进行的临床试验相结合。
英文摘要
ABSTRACT / SUMMARY
There is currently a clear need for objective brain based outcome measures for autism
spectrum disorders (ASD). Outcome measures are measures that are used before a clinical or
intervention trial begins, to get a baseline measure, and are then repeated at the end of the trial,
to determine whether changes have occurred as a result of the intervention. Currently, the vast
majority of outcome measures used in ASD treatment trials are based on behavioral measures,
usually parental, and are therefore subjective by nature. Even in double blind trials, there is still
risk of contamination of the measures from a placebo effect. Therefore, there is a clear need for
objective outcome measures in the field. One such class of potential outcome measures is
brain-based. Since the most oft-found clinical lab equipment is a simple 10-20 EEG system, the
ideal brain-based outcome measures for ASD would use such a system. However, the vast
majority of known biomarkers for ASD, that would in theory have outcome measure potential,
are derived using equipment that is far too complex and expensive to replicate in clinical
settings, and using paradigms that require a setup and analyses methods that are too complex
to carry out clinically on a large number of subjects with high inter-subject variability.
Here, we propose a novel approach to this problem. We propose to translate three
biomarkers for ASD identified in our lab or by other groups using magnetoencephalography
(MEG), to clinical EEG. The study will focus on MEG-based biomarkers already known to be
associated with ASD diagnosis and severity, one in the auditory domain, one in the tactile
domain, and one using a relatively novel analysis of resting state data. The translation to clinical
EEG would be judiciously carried out, by combining MEG and EEG data collection, and then
using a data driven approach to validate the results. We will also develop a user-friendly toolbox
as part of the process, to standardize data analysis and make the process easily portable and
uniform across multiple sites.
The initial development will be carried out using 10 typically developing participants, and
10 ASD participants, using high density simultaneous EEG/MEG data collection. The results will
then be validated using 15 new participants per group, and simultaneous “clinical EEG” (i.e.
minimal sensor locations) and high-density MEG data collection. This proof of concept proposal
will take place entirely onsite, and will form the basis for future offsite studies across multiple
clinical settings, ideally in conjunction with ongoing clinical trials.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
High Temporal Resolution Study of Resting-State Cerebro-Cerebellar Functional Connectivity in ASD
-
批准号:10380250
-
项目类别:
-
资助金额:$25.2万
-
财政年份:2021
-
负责人:Tal Kenet
-
依托单位:
High Temporal Resolution Study of Resting-State Cerebro-Cerebellar Functional Connectivity in ASD
-
批准号:10541222
-
项目类别:
-
资助金额:$21.0万
-
财政年份:2021
-
负责人:Tal Kenet
-
依托单位:
Testing the Bottom-Up vs Top-Down Imbalance Hypothesis of ASD
-
批准号:10431883
-
项目类别:
-
资助金额:$79.17万
-
财政年份:2018
-
负责人:Tal Kenet
-
依托单位:
Testing the Bottom-Up vs Top-Down Imbalance Hypothesis of ASD
-
批准号:10208649
-
项目类别:
-
资助金额:$79.65万
-
财政年份:2018
-
负责人:Tal Kenet
-
依托单位:
Functional connectivity substrates of social and non-social deficits in ASD
-
批准号:8728973
-
项目类别:
-
资助金额:$69.81万
-
财政年份:2013
-
负责人:Tal Kenet
-
依托单位:
Functional connectivity substrates of social and non-social deficits in ASD
-
批准号:8577455
-
项目类别:
-
资助金额:$71.96万
-
财政年份:2013
-
负责人:Tal Kenet
-
依托单位:
Functional connectivity substrates of social and non-social deficits in ASD
-
批准号:9066026
-
项目类别:
-
资助金额:$70.24万
-
财政年份:2013
-
负责人:Tal Kenet
-
依托单位:
Functional connectivity substrates of social and non-social deficits in ASD
-
批准号:9291492
-
项目类别:
-
资助金额:$55.92万
-
财政年份:2013
-
负责人:Tal Kenet
-
依托单位:
Coherence and Temporal Dynamics in Auditory Cortex of Children with Autism
-
批准号:7631322
-
项目类别:
-
资助金额:$8.83万
-
财政年份:2008
-
负责人:Tal Kenet
-
依托单位:
海外基金